Eiger Biopharmaceuticals Inc logo

Eiger Biopharmaceuticals Inc Share Price (NASDAQ: EIGR)

▲

-1.72

(-100%)

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 9 Apr 2024

Check the interactive Eiger Biopharmaceuticals Inc Stock chart to analyse performance

Eiger Biopharmaceuticals Inc Key Stats

Check Eiger Biopharmaceuticals Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.725
Open
$1.9
Market Capitalization
$3.3M
Today's Volume
$136.3K
Revenue TTM
$14.7M
EBITDA
$-83.4M
Earnings Per Share (EPS)
$-58.5
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-225.93%

Global Institutional Holdings in Eiger Biopharmaceuticals Inc

  • Name

    Holdings %

  • Ameriprise Financial Inc

    16.91%

  • Propel Bio Management LLC

    9.89%

  • 683 Capital Management LLC

    4.73%

  • Vanguard Group Inc

    4.10%

  • BlackRock Inc

    1.32%

  • Geode Capital Management, LLC

    0.86%

Analyst Recommendation on Eiger Biopharmaceuticals Inc Stock

Rating
Trend

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Eiger Biopharmaceuticals Inc(by analysts ranked 0 to 5 stars)

About Eiger Biopharmaceuticals Inc

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Organization
Eiger Biopharmaceuticals Inc
Employees
56
CEO
Dr. David Apelian M.B.A., M.D., Ph.D.
Industry
Health Technology

Important FAQs about investing in EIGR Stock from India :

What is Eiger Biopharmaceuticals Inc share price today?

Eiger Biopharmaceuticals Inc share price today is as on at the close of the market. Eiger Biopharmaceuticals Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Eiger Biopharmaceuticals Inc share?

Eiger Biopharmaceuticals Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Eiger Biopharmaceuticals Inc stock price today i.e. is closed at , lower by 100% versus the 52 week high.

How to invest in Eiger Biopharmaceuticals Inc Stock (EIGR) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Eiger Biopharmaceuticals Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Eiger Biopharmaceuticals Inc Shares .

What is the minimum amount required to buy Eiger Biopharmaceuticals Inc Stock (EIGR) from India?

Indian investors can start investing in Eiger Biopharmaceuticals Inc (EIGR) shares with as little as ₹87.7613 or $1 (as of September 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹877.61 in Eiger Biopharmaceuticals Inc stock (as per the Rupee-Dollar exchange rate as on September 18, 2025). Learn more about fractional shares .

What are the returns that Eiger Biopharmaceuticals Inc has given to Indian investors in the last 5 years?

Eiger Biopharmaceuticals Inc stock has given 0.0% share price returns and 19.34% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?